Table 7 Characteristics of the study population (Validation Study).
Variable | Type 2 diabetes Patients |
|---|---|
N = 30 | |
Age (years) | 55.0 ± 5.7 |
Time since diagnosis of diabetes (years) | 4.3 ± 2.9 |
Body mass index (kg/m2) | 28.0 ± 3.3 |
Waist circumference (cm) | 101.1 ± 10.2 |
Subcutaneous fat volume (mL) | 648.7 ± 272.6 |
Visceral fat volume (mL) | 422.8 ± 207.8 |
Systolic blood pressure (mm Hg) | 126.9 ± 11.0 |
Diastolic blood pressure (mmHg) | 75.4 ± 8.6 |
Heart rate (bpm) | 64.9 ± 9.4 |
Concomitant medication N (%) | |
Statin | 12 (40.0) |
Any antihypertensive medication | 13 (43.3) |
β-Blocker | 1 (3.3) |
Diuretic | 1 (3.3) |
ACE inhibitor | 8 (26.7) |
ARB | 4 (13.3) |
Calcium antagonist | 1 (3.3) |
HbA1c (%) | 7.0 ± 1.0 |
Plasma fasting glucose (mmol/L) | 7.8 ± 1.3 |
Plasma fasting insulin (pmol/L) | 79.7 ± 45.6 |
Total cholesterol (mmol/L) | 4.9 ± 1.2 |
LDL cholesterol (mmol/L) | 2.8 ± 0.8 |
HDL cholesterol (mmol/L) | 1.1 ± 0.3 |
Plasma triglycerides (mmol/L) | 2.3 ± 2.8 |
Plasma NEFA (mmol/L) | 0.5 ± 0.2 |
us-CRP (mg/L) | 12.8 ± 29.3 |
NT-proBNP (ng/L) | 30.9 ± 21.7 |
Parameters of cardiac dimensions and function | |
LV mass (g) | 106.1 ± 14.3 |
LV end-systolic volume (mL) | 65.5 ± 14.8 |
LV end-diastolic volume (mL) | 157.6 ± 25.1 |
LVMV-ratio (g/mL) | 0.7 ± 0.1 |
LV Stroke volume (mL) | 92.2 ± 14.5 |
LV Ejection Fraction (%) | 58.6 ± 5.1 |
Cardiac index (L/min * m−2) | 2789.9 ± 438.8 |
E peak filling rate (mL/s) | 412.1 ± 82.3 |
E-decpeak (mL/s2*10−3) | −3.4 ± 1.0 |
E-decmean (mL/s2*10−3) | −2.2 ± 0.7 |
E/A peak flow | 1.1 ± 0.3 |
E/Ea | 10.6 ± 4.6 |
Neutral lipid content (%) | 0.8 ± 0.5 |
